Results 31 to 40 of about 11,226 (207)

Daratumumab, bortezomib, and dexamethasone for multiple myeloma [PDF]

, 2016
BACKGROUND Daratumumab, a human IgG kappa monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy in heavily pretreated patients with multiple myeloma, as well as in ...
Mark, T M, Weisel, Katja, Qi, M, Schecter, J, Masszi, T, Munder, Markus, Mateos, Maria V., Spicka, Ivan, Hungria, Vania, Schecter, Jordan, CASTOR Investigators, Deraedt, W, Qi, Ming, Deraedt, William, Spencer, Andrew, Mateos, MV, Spencer, A, Chanan-Khan, A, Sonneveld, Pieter, Ahmadi, T, Munder, M, Palumbo, A, Qin, X, CAVO, MICHELE, Chanan Khan, Asher, Palumbo, Antonio, Nooka, Ajay K., Beksac, Meral, Spicka, I, Sonneveld, P, Amin, Himal, Amin, H, Mark, TM, Ahmadi, Tahamtan, Hungria, V, FOA, Roberto, Nooka, AK, Mark, Tomer M., Qin, Xiang, Beksac, M, Palumbo, Ali, Chanan-Khan, Asher, Weisel, K, Masszi, Tamas   +43 more
core   +1 more source

B-cell targeting with anti-CD38 daratumumab: implications for differentiation and memory responses

Life Science Alliance, 2023
Daratumumab is an anti-CD38–targeting antibody that depletes plasma cells. This study shows that daratumumab also disturbs humoral immune responses beyond depletion only and may be used as therapeutic in B cell–mediated autoimmune diseases.
Dorit Verhoeven, Lucas Grinwis, Casper Marsman, Machiel H Jansen, Ester MM Van Leeuwen, Taco W Kuijpers   +5 more
doaj   +1 more source

Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma [PDF]

, 2018
BACKGROUND The combination of bortezomib, melphalan, and prednisone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation.
San-Miguel, Jesus, Mateos, M. -V., Fujisaki, T., Suzuki, K., Crist, Wendy, Doyen, C., William Deraedt, Zsolt Nagy, Carson, R., Shelekhova, Tatiana, Qi, Ming, Mamta Garg, Wang, J., Lucio, Paulo, Kenshi Suzuki, Garg, Mamta, Chiu, Christopher, Tatiana Shelekhova, Crist, W., Chiu, C., Foa R., Iosava, Genadi, Cavo, M., Robin Carson, Jianping Wang, Liberati, Anna M., Shelekhova, T., Nguyen, H., Jakubowiak, Andrzej, Doyen, Chantal, Deraedt, W., Ludek Pour, San Miguel Izquierdo, Jesús Fernando, San-Miguel, Jesus for the ALCYONE Trial Investigators, Andre Crepaldi, Campbell, Philip, Anna M. Liberati, Yoon, S. -S., Iosava, G., Qi, M., Suzuki, Kenshi, Carson, Robin, Michele Cavo, Philip Campbell, ALCYONE Trial Investigators, Ming, Qi, Pour, Ludek, Yoon, Sung-Soo, Jesus San-Miguel, Dimopoulos, M. A., Campbell, P., Paulo Lucio, Cavo, Michele, Sung-Soo Yoon, Liberati, A. M., Crepaldi, Andre, Grosicki, Sebastian, Andrzej Jakubowiak, Chantal Doyen, Polina Kaplan, Liberati, Anna M, Wang, Jianping, Kaplan, P., Deraedt, William, Huong Nguyen, Nagy, Z., Sebastian Grosicki, Crepaldi, A., María-Victoria Mateos, Christopher Chiu, Garg, M., Mark Cook, Dimopoulos, Meletios A., Knop, S., Dimopoulos, Meletios A, Grosicki, S., Pour, L., Jakubowiak, A., Tomoaki Fujisaki, Mateos, María-Victoria, Stefan Knop, Ming Qi, Mateos Manteca, María Victoria, Genadi Iosava, Knop, Stefan, Lucio, P., Wendy Crist, San-Miguel J., Nagy, Zsolt, Fujisaki, Tomoaki, Cook, Mark, Cook, M., Nguyen, Huong, Kaplan, Polina, Meletios A. Dimopoulos   +94 more
core   +3 more sources

Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma

Hematology, Transfusion and Cell Therapy, 2021
Introduction: Daratumumab is a CD38-targeting monoclonal antibody with established efficacy and safety in patients with relapsed or refractory multiple myeloma (RRMM).
Edvan de Queiroz Crusoé, Flávia Cristina Fernandes Pimenta, Angelo Maiolino, Nelson Siqueira de Castro, Huiling Pei, Damila Trufelli, Mariana Fernandez, Luciana Barreto Herriot   +7 more
doaj   +1 more source

Daratumumab in AL amyloidosis [PDF]

, 2022
Light-chain amyloidosis has come far, with the first treatment getting regulatory approval in 2021. Daratumumab-based regimens achieve deep hematologic and organ responses, offering a new therapeutic backbone. Early identification, correct fibril typing,
Sanchorawala, V, Wechalekar, AD
core  

Daratumumab-225Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors

OncoImmunology, 2019
Daratumumab is an anti-CD38 directed monoclonal antibody approved for the treatment of multiple myeloma (MM) and functions primarily via Fc-mediated effector mechanisms such as complement-dependent cytotoxicity (CDC), antibody-dependent cell cytotoxicity
Wojciech Dawicki, Kevin J.H. Allen, Rubin Jiao, Mackenzie E. Malo, Muath Helal, Mark S. Berger, Dale L. Ludwig, Ekaterina Dadachova   +7 more
doaj   +1 more source

Pharmacology of Daratumumab

, 2022
Daratumumab was developed by Janssen Biotech and Genmab Inc. And first approved in 2015. It was initially approved for relapsed/refractory multiple myeloma, has considerably improved multiple myeloma outcomes either as monotherapy or in combination with ...
Audu, Onyejem Comfort
core  

Subcutaneous daratumumab in Chinese patients with relapsed or refractory multiple myeloma: an open-label, multicenter, phase 1 study (MMY1010)

Blood Science
Despite recent progress in multiple myeloma (MM) treatments, most patients will relapse and require additional treatment. Intravenous daratumumab, a human IgGκ monoclonal antibody targeting CD38, has shown good efficacy in the treatment of MM.
Gang An, Zheng Ge, Hongmei Jing, Jing Liu, Guoping Yang, Ru Feng, Zhongyuan Xu, Ming Qi, Jianping Wang, Juanjuan Song, Wei Zhou, Binbin Sun, Dian Zhu, Xi Chen, Canchan Cui, Lugui Qiu   +15 more
doaj   +1 more source

CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients

Journal of Translational Autoimmunity, 2019
Autoantibody-producing plasma cells are frequently resistant to conventional immunosuppressive treatments and B-cell depletion therapy. As a result of this resistance, autoreactive plasma cells survive conventional therapy, resulting in persistent ...
Kristine A. Frerichs, Christie P.M. Verkleij, Patricia W.C. Bosman, Sonja Zweegman, Henny Otten, Niels W.C.J. van de Donk   +5 more
doaj   +1 more source

Daratumumab for immune thrombotic thrombocytopenic purpura [PDF]

, 2022
Immune thrombotic thrombocytopenic purpura (iTTP) is a life-threatening thrombotic microangiopathy. It is caused by a severe ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 motifs, 13) deficiency due to circulating autoantibodies ...
Hegemann, Inga, Stehle, Gregor Thomas, Kremer Hovinga, Johanna A; https://orcid.org/, Studt, Jan-Dirk, Pfleger, Claudia, Van den Berg, Jana, Kremer Hovinga, Johanna A., Holbro, Andreas   +7 more
core   +1 more source